상대정맥증후군의 방사선치료 = Radiation Therapy for Superior Vena Cava Syndrome

국문 초록 (Abstract)

목 적: 악성종양에 의한 상대정맥증후군에서 방사선치료 후의 증상완화율, 생존율, 예후인자를 알아보기 위해
연구를 시행하였다. 대상 및 방법: 1988년부터 2003년까지 계명의대 동산의료원 방사선종양학과에서 상대정맥증후군으로 방사선치료를 받고 추적관찰이 가능했던 72명의 환자를 대상으로 하였다. 남자가 64명, 여자가 8명이었으며 연령은 10세에서 83세로 평균 61세였고 원인으로는 폐암 64명, 전이성 폐암 4명, 림프종 2명, 흉선종 2명이었다. 방사선
치료는 모든 환자를 900 cGy 이상 조사하였으며 총방사선량이 6,600 cGy까지 조사하여 중앙값은 4,000 cGy였
다. 추적기간은 1개월에서 180개월로 중앙값 5.6개월이었다. 결 과: 주증상은 호흡곤란 84.7%, 안면부종 81.9%, 팔부종 22.2%, 경정맥확장 25%, 애성 12.5%, 안면홍조 5.6%순이었다. 방사선치료 후 80.6%에서 매우 우수(excellent) 또는 우수(good)한 증상완화를 보였고 19.4%에서는 변화가 없거나 경미한(minimal) 증상완화가 있었다. 전체 환자의 중앙생존기간은 5.1개월이었고 2년 생존율은 17.7%, 5년 생존율은 14.8%이었다. 폐암환자에서는 각각 4.3개월, 16.7%, 13.4%였다. 단변량분석에서 폐암환자는 총방사선량을 30 Gy 초과로 조사 받은 군이 그 미만의 방사선을 조사 받은 군보다 통계적으로 유의하게 생존율의 차이를 보였다(2YSR; 30 Gy 초과 25.6%, 30 Gy 이하 6.7%, p＜0.01). 다변량분석에서도 폐암에 의한 상대정맥증후군의 예후인자로는 총방사선량(p＜0.01)과 연령(p＜0.05)이 통계적으로 유의한 인자였다. 비소세포성
폐암이 소세포성폐암보다 생존율이 높았으나 통계적으로 유의하지 않았다. 결 론: 악성종양에 의한 상대정맥증후군에서 방사선치료는 효과적인 치료방법이며 폐암으로 인한 상대정맥증후군에서 총방사선량을 30 Gy 이상 조사하는 적극적인 치료로 생존율이 연장될 수 있으리라 생각된다.

다국어 초록 (Multilingual Abstract)

Purpose: We studied the effect of such variables as the symptom improvement rate, survival and prognostic
factors on the treatment results of radiation therapy for Superior Vena Cava Syndrome (SVCS). Materials and Methods: From 1988 to 2003, seventy two patients with SVCS were treated with radiation therapy at the Department of Radiation Oncology, Keimyung University Dongsan Medical Center. The patients' ages ranged from 10 to 83 years old with the median age being 61, and sixty four patients were male. For the causes of the SVCS, 64 patients had lung cancer, four had metastatic lung cancer, two had malignant lymphoma and two had thymoma. The radiotherapy was delivered with 6-MV X-rays and all patients received above 900 cGy up to 6,600 cGy, with the median dose being 4,000 cGy. The follow-up periods were from 1 to 180 months with a median of 5.6 months.
Results: The main clinical manifestations were dyspnea (84.7%), facial edema (81.9%), arm edema (22.2%),
neck vein distension (25%), hoarseness (12.5%) and facial plethora (5.6%). Eighty percent of patients achieved
excellent to good symptom improvement and 19.4% experienced minimal improvement. The median survival
period was 5.1 months, and overall survival rates were 17.7% at 2 years (2YOS) and 14.8% at five years
(5YOS) for all the patients. The median survival period, the two and five year disease free survival rates were
4.3 months, 16.7% and 13.4% for the lung cancer patients, respectively. The total tumor dose was a statistically
significant survival factor on the univariate analysis for the patients with lung cancer (2YSR; ＞30 Gy, 25.6%, ≤ 30 Gy 6.7%, p＜0.01). On the multivariated analysis, a higher total tumor dose (p＜0.01) and younger age (p＜
0.05) were statistically significant factors of survival for the lung cancer patients. Patients with NSCLC showed better survival than did the patients with SCLC, but this was not statistically significant (p＞0.05).
Conclusion: Radiation therapy for the patients with SVCS due to malignancy could be an effective treatment.
We considered that radiation therapy above 30 Gy of the total tumor dose may improve survival for SVCS due
to lung cancer.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 토 론

참고문헌 (Reference)

1 "some epidemiological observations in 76 patients" 433-440, angiology1974

2 "Treatment of malignant superior vena cava obstruction:metal stents or radiation therapy" 8 : 781-788, 1997

3 "The use of the Wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava" 48 : 381-385, 1993

4 "The superior vena cava syndome" 227 : 46-56, 1954

5 "The role of venography and surgery in the management of patients with superior vena cava obstruction" 41 : 158-163, 1986

6 "The CIBA Collection of Medical Illustrations" CIBA Pharmaceutical Company 1979

7 "Superior vena caval obstruction with lung cancer" 6 : 437-442, 1968

8 "Superior vena cava syndrome:etiology,diagnosis,and treatment" 1 : 54-64, 192

9 "Superior vena cava syndrome.The myth-the facts" 141 : 1114-1118, 1990

10 "Superior vena cava syndrome induced by bronchogenic carcinoma:is this an oncological emergency" 37 : 363-366, 1993

11 "Superior vena cava syndrome in small-cell lung cancer" 153 : 384-387, 1993

12 "Superior vena cava syndrome in small cell lung carcinoma" 52 : 2165-2172, 1983

13 "Superior vena cava syndrome in lung cancer:an analysis of 54 cases" 11 : 568-573, 1995

14 "Superior vena cava obstruction in small-cell lung cancer" 38 : 513-520, 1997

15 "Superior vena cava obstruction in primary cancer of the lung" 31 : 470-478, 1949

16 "Small cell lung cancer with and without superior vena cava syndrome:a multivariate analysis of prognostic factors in 408 cases" 33 : 77-82, 1995

17 "Safety and efficacy of thrombolytic therapy for superior vena cava syndrome" 99 : 54-59, 1991

18 "Safety and efficacy of thrombolytic therapy for superior vena cava syndrome" 99 : 54-59, 1991

19 "Role of irradiation in the management of superior vena cava syndrome" 13 : 531-539, 1987

20 "Hypofractionated radiation therapy in the treatment of superior vena cava syndrome" 10 : 221-228, 1993

21 "High daily dose for rapid decompression Carcinoma of the broncus" 276-297, 1971

22 "Gianturco self-expanding stents:clinical experience in the vena cava and large veins" 15 : 328-333, 1992

23 "Evaluating the superior vena cava syndrome" 245 : 951-953, 1981

24 "Endovascular stenting as a first choice for the palliation of superior vena cava syndrome" 19 : 519-522, 2004

25 "Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors.Comparison with conventional treatment" 39 : 669-674, 1998

26 "Bypass of superior vena cava:Six years' experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease" 83 : 326-338, 1982

27 "Approach to the patient who presents with superior vena cava obstruction" 103 (103): 1993

28 "A reassessment of the clinical implications of the superior vena caval syndrome" 2 : 961-969, 1984

29 "A contemporary perspective on superior vena cava syndrome" 160 : 207-211, 1990

30 "A case of successful implantation of a DDD type permanent pacemaker in a patient with persistent left superior and absent right superior vena cava" 34 : 623-626, 2004